Press Releases
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering
Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Corbus Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
